Patents by Inventor David L. Foster

David L. Foster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7211560
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: May 1, 2007
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Patent number: 6962795
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: November 10, 1993
    Date of Patent: November 8, 2005
    Assignee: Dendreon Corporation
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Publication number: 20040259769
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Application
    Filed: December 29, 2003
    Publication date: December 23, 2004
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Patent number: 6818616
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: November 16, 2004
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Patent number: 6756211
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: May 11, 1993
    Date of Patent: June 29, 2004
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Patent number: 6670323
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: December 30, 2003
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Patent number: 5919900
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: July 6, 1999
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster
  • Patent number: 5789178
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 4, 1998
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Patent number: 5747296
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Also provided are recombinant Neutrophil Inhibitory Factors which also which inhibit neutrophil activity. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions and recombinant Neutrophil Inhibitory Factors are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: May 5, 1998
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Patent number: 5708141
    Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes, particularly of the genus Ancylostoma. These compositions are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: January 13, 1998
    Assignee: Corvas International, Inc.
    Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
  • Patent number: 4389586
    Abstract: The magnet frame of a dynamoelectric machine comprises a removable, generally cylindrical inner member concentrically disposed inside a cylindrical outer member. The inner member is supported in a cantilever fashion at only one of its ends, and most of its outside surface is normally separated by a relatively small circumferential gap from the cooperating inside surface of the outer member. The outer member of the frame rotatably supports the hub of a motorized wheel, which hub is coupled via a torque tube and gearing to a rotor inside the inner member. Conventional means is provided in the inner member for producing a field of magnetic flux in both the magnet frame and the rotor, and the path of this flux will include parallel branches in the inner and outer frame members.
    Type: Grant
    Filed: February 22, 1982
    Date of Patent: June 21, 1983
    Assignee: General Electric Company
    Inventors: David L. Foster, John F. Haupt, Malcolm W. Waite